BridgeBio Pharma, Inc. Proceeds from Debt, Net of Issuance Costs
BridgeBio Pharma, Inc. (BBIO) reported Proceeds from Debt, Net of Issuance Costs of $450.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-02-20
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for the quarter ending 2021-12-31 was $431.30M.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for the quarter ending 2021-09-30 was $0.00.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for the quarter ending 2019-12-31 was $17.15M, a 13.58% decline year-over-year.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for the quarter ending 2019-09-30 was $0.00.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $450.00M.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $0.00.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BridgeBio Pharma, Inc. proceeds from debt, net of issuance costs for fiscal 2021 was $456.30M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $450.00M 10-K · filed 2025-02-20 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-20 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $431.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $431.30M derived: sum of 2 quarters · filed 2024-02-22 | $456.30M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $25.00M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $25.00M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $17.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $17.15M derived: sum of 2 quarters · filed 2022-02-25 | $36.94M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $19.79M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $19.79M 10-Q · filed 2020-08-11 | |||
| 2018-12-31 | $19.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $56.44M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $36.59M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |